Hair loss treatments could soon involve a specialized comb that delivers targeted electrical pulses and active biological molecules directly to hair follicles.
Researchers at Beihang University in Beijing developed the prototype device, named “Detangle,” to combat hormone-driven hair loss in laboratory experiments.
The study, published on November 3, 2026, in Nature Communications, details how the device achieved nearly complete hair regrowth in male mice over a 28-day period. Feng Liu, Fuqi Yao, and their 16 co-authors designed the comb to address androgenetic alopecia.
How the Experimental Comb Delivers Deep Treatment
The device features two types of tines with unequal lengths that function as electrodes to generate localized electrical fields. This layout creates an electrical field strength 2.63 times higher than arrangements with equal-length tines, while driving the therapeutic field roughly nine times deeper into the skin than conventional topical applications.
The electrical impulses trigger electroporation, a process that temporarily alters cell membrane permeability to ease the transfer of macromolecules. Tests with a marker substance showed the mechanism carried material approximately 660 micrometers deep into the skin within one second, compared to about 74 micrometers for simple topical application.
Combining Electrical Stimulation With Genetic Therapeutics
The treatment relies on two experimental nucleic acid components delivered alongside the electrical pulses. One component is a VEGFA plasmid DNA designed to stimulate blood vessel formation around hair follicles, while the second component uses a short RNA to suppress 5-alpha-reductase 2, an enzyme involved in producing dihydrotestosterone, according to Scinexx.
A DNA plasmid carries the blueprint for VEGF-A, a growth factor intended to stimulate the formation of fine blood vessels around hair follicles. The second component is a short RNA that aims to suppress production of the enzyme 5-alpha-reductase 2, which participates in the formation of dihydrotestosterone that drives hair loss in genetically susceptible follicles.
Beihang University traces its roots to 1952, when aerospace engineering departments from eight elite institutions — among them Tsinghua University, Peiyang University, Xiamen University, Sichuan University and Chongqing University — were merged to form Beijing Aeronautics College in Haidian, Beijing.
It became the first aerospace higher education institution in the People’s Republic of China and was later renamed Beijing University of Aeronautics and Astronautics. Today it operates one national laboratory and nine national key laboratories, including four defense technology key laboratories, and has produced more than 40 research achievements that were first in China.
The research team observed that the combined application surpassed conventional pharmaceutical treatments used in the trial. Tissue analyses also revealed improved local blood circulation and activated hair follicles without causing short-term skin inflammation or abnormal changes in measured inflammatory markers.
For the test, the back fur of male mice was removed and the skin repeatedly treated with testosterone to induce features of hormone-driven hair loss. One group received the combination of electrostimulation and both molecules every three days. Comparison groups were treated with topical minoxidil or oral finasteride. The combination of both molecules also achieved more hair growth than their respective individual delivery. Analyses of skin samples from the animals indicated that the stimulation altered several metabolic and growth pathways, pointing among other things to involvement of the Wnt/beta-catenin signaling pathway, which influences hair follicle renewal.
Researchers caution that the findings remain strictly preclinical. Human hair follicles and growth cycles differ from those of mice, and the animal test subjects experienced hair loss induced artificially by testosterone rather than the gradual progression seen in humans.
“Dieser Ansatz beschleunigt das Haarwachstum im Mausmodell für androgenetische Alopezie innerhalb eines Monats auf nahezu 100 Prozent und übertrifft damit die Ergebnisse herkömmlicher oraler oder äußerlich angewendeter Medikamente,” the researchers said in the study, according to Smartup News.
Before human application, the safety of the electrical stimulation, possible side effects of the genetic agents, and the long-term effect must be investigated. Clinical trials must evaluate the long-term safety, potential side effects, and efficacy of repeated nucleic acid delivery to the human scalp before the device can receive regulatory approval for public use.
More on Nature Communications
Worth a look